A Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AB-16B5 in Subjects With an Advanced Solid Malignancy

Alethia Biotherapeutics1 site in 1 country15 target enrollmentApril 2015

ConditionsSolid Tumor Metastatic Cancer

InterventionsAB-16B5

DrugsAB-16B5

Overview

Phase: Phase 1
Intervention: AB-16B5
Conditions: Solid Tumor
Sponsor: Alethia Biotherapeutics
Enrollment: 15
Locations: 1
Primary Endpoint: Number of participants with an adverse event as a measure of safety and tolerability
Status: Completed
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a Phase 1 clinical study to investigate the safety, pharmacokinetics and pharmacodynamics of AB-16B5 in patients with an advanced solid malignancy. AB-16B5 is a humanized monoclonal antibody that inhibits the activity of the secreted form of clusterin (sCLU), a potent inducer of the epithelial-to-mesenchymal transition (EMT). Eligible subjects will have a disease that has been refractory to prior therapy and is unlikely to benefit from known therapies.

Registry

clinicaltrials.gov

Start Date

April 2015

End Date

January 2017

Last Updated

8 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Alethia Biotherapeutics

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects with a histologically or cytologically confirmed advanced solid malignancy that has been refractory to prior therapy and is unlikely to benefit from known therapies.
•Subjects may have measurable or non-measurable but evaluable disease.
•Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 and an estimated life expectancy of at least 12 weeks.
•Subjects must be ≥ 18 years old.
•Male, or female subjects who are post-menopausal (amenorrheic for at least 12 months), or surgically or biologically sterile. Females of childbearing potential with a negative serum pregnancy test prior to entering the study and using adequate forms of contraception for the duration of the study, including 30 days after the last treatment. Males should avoid fathering children during the course of the study, and adequate methods of contraception should be used by both male and female subjects. Subjects and their partners with reproductive potential must use an effective contraceptive method while the subject is on the study treatment and for 30 days after the last treatment.
•Subjects must have adequate organ and immune function as indicated by the following laboratory values:
•ANC ≥ 1.5 X 109/L
•Platelets \> 100 X 109/L
•Hemoglobin ≥ 90 g/L
•Serum creatinine ≤ 132 µmol/L

Exclusion Criteria

•Subjects with medical, social, or psychosocial factors that, in the opinion of the Investigator, could impact safety or compliance with study procedures.
•Prior cancer therapy including surgery, radiotherapy, chemotherapy, hormonal and biological therapies within 3 weeks prior to study treatment.
•Uncontrolled brain metastases.
•Uncontrolled infection.
•Clinically significant ECG abnormalities.
•Known hypersensitivity of Grade \> 2 to previous monoclonal antibody therapy.
•History of alcohol or other substance abuse within the last year.
•Use of another investigational agent in a clinical trial within the last 4 weeks prior to study treatment.
•Female subjects who are pregnant or lactating, including females with a positive pregnancy test at screening must be excluded.

Arms & Interventions

AB-16B5

Single-arm study of AB-16B5 given as a 60-minute intravenous weekly infusion. One cycle of treatment will consist of 21 days. The dose levels that will be assessed are 1.5, 3.0, 6.0, 9.0 and 12 mg/kg.

Intervention: AB-16B5

Outcomes

Primary Outcomes

Number of participants with an adverse event as a measure of safety and tolerability

Time Frame: Up to treatment discontinuation + 30 days with an estimated treatment duration of 6 to 24 weeks

Secondary Outcomes

Determination of plasma concentrations of AB-16B5(Several time-points during Cycle 1 and Cycle 2 for a total of 6 weeks)
Objective tumor responses in subjects with measurable disease according to RECIST(Up to treatment discontinuation + 30 days with an estimated treatment duration of 6 to 24 weeks)
Monitoring of epithelial-to-mesenchymal (EMT) and stem cells biomarkers in peripheral blood circulating tumor cells and paired tumor biopsies(Up to treatment discontinuation + 30 days with an estimated treatment duration of 6 to 24 weeks)